

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
202.2D2APPLICATION NO.
10/602,330SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Clarence N. Ahlem, et alFILING DATE
June 23, 2003GROUP
1617

U.S. PATENT DOCUMENTS

EXAMINER Approval Date	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	6,924,274 B2	08-02-05	Lardy et al			11-03-98
	6,686,388 B2	02-03-04	Dudek et al			10-14-99
	6,350,738	02-26-02	Savage et al			01-19-99
	5,776,923	07-07-98	Labrie			
	5,656,621	08-12-97	Schwartz et al			
	5,595,721	01-21-97	Kaminski et al			
	5,478,566	12-26-95	Loria			
	5,175,154	12-29-92	Schwartz et al			
	5,028,631	07-02-91	Schwartz et al			
	4,898,694	02-06-90	Schwartz et al			
	2,845,381	07-29-58	Tindall et al			

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	DOCUMENT PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	2005/0159366 A1	Ahlem et al			
	2005/0101581 A1	Ahlem et al			
	2005/0075321 A1	Ahlem et al			
	2004/0220161 A1	Ahlem et al			
	2004/0220114 A1	Ahlem et al			
	2004/0138187 A1	Ahlem et al			
	2004/0127474 A1	Dudek et al			10-14-99
	2004/0116359 A1	Ahlem et al			
	2004/0097406 A1	Ahlem et al			
	2004/0043973 A1	Ahlem et al			

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.2D2	APPLICATION NO. 10/602,330
	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE June 23, 2003	GROUP 1617

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL	DOCUMENT PUBLICATION NUMBER	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	2003/0083231 A1	Ahlem et al			
	2003/0060425 A1	Ahlem et al			
	2002/0187973 A1	Labrie			06-11-99
	2001/034337 A1	Dudek et al			10-14-99

FOREIGN PATENT DOCUMENTS

EXAMINER Approval Date	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	DE 38 12 595 C2	07-03-97	Germany			X	
	GB 876,009	8-30-61	United Kingdom				
	WO 97/13500 A2	04-17-97	PCT				

EXAMINER Approval Date	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PAGES, ETC.)
	Adams et al, Metabolism of 17 β -estradiol and the adrenal-derived estrogen 5-androstene-3 β ,17 β -diol (hermaphrodiol) in human mammary cell lines, <i>Ann. N.Y. Acad. Sci.</i> 595:93-105 1990
	Adams et al, Adrenal dehydroepiandrosterone and human mammary cancer, <i>Cancer Research</i> 38:4036-4040 1978
	Allen et al, Pathologic alterations observed in Rhesus monkeys given total body X-irradiation and bone marrow transplants, <i>Amer. J. Vet. Res.</i> 27(119): 1103-1112 1966
	Baker et al, Comparison of interleukin-1 alpha gene expression and protein levels in the murine spleen after lethal and sublethal total-body irradiation, <i>Radiation Res.</i> 143(3): 320-326 1995
	Barkve et al, Cyclic neutropenia. Report of a case treated with high doses of testosterone, <i>Acta Med. Scand.</i> 182(4):503-507 1967
	Beetz, A., et al, Induction of interleukin 6 by ionizing radiation in a human epithelial cell line: Control by corticosteroids, <i>Int. J. Radiat. Biol.</i> , 72:33-43 1997
	Behrends et al, Ionizing radiation induces human intercellular adhesion molecule-1 <i>in vitro</i> , <i>J. Invest. Dermatol.</i> 103(5):726-730 1994

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.2D2	APPLICATION NO. 10/602,330
	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE June 23, 2003	GROUP 1617

EXAMINER Approval Date	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PAGES, ETC.)
	Besa et al, Effective erythropoiesis induced by 5 β -pregnane-3 β -hydroxy-20-one in squirrel monkeys, <i>J.Clin. Invest.</i> 52:2278-2282 1973
	Borsa et al, Radioprotective effects of madiol and leucotrofina studied by the dynamic changes of some metabolic processes in the thymus and the liver of X-irradiated rats, <i>Revue Roumaine de Biologie, Serie de Biologie Animale</i> 26(1):63-67 1981
	Broerse et al, Mortality of monkeys after exposure to fission neutrons and the effect of autologous bone marrow transplantation, <i>Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med.</i> 34(3):253-264 1978
	Canman, C. E., et al, Signal transduction. Three paths to stress relief. <i>Nature</i> , 384:213-214 1996
	Casey, M. L., et al, Dehydroepiandrosterone therapeutics: Acetylation of DHA in mouse liver, <i>J. Steroid Biochem</i> , 30:149-154 1988
	Chatterton, R.T., et al, Pharmacokinetics and pharmacodynamics of anordrin (2 α ,17 α -diethynyl-A-nor-5 α -androstane-2 β ,17 β -diol dipropionate), <i>Steroids</i> , 59:217-223 1994
	Chiang et al, Delayed molecular responses to brain irradiation, <i>Int. J. Radiat. Biol.</i> 72(1):45-53 1997
	Claesson et al, Stimulation of human myelopoiesis by leukotriene B ₄ , <i>Biochem. Biophys. Res. Commun.</i> 131(2):579-585 1985
	Clark et al, Hprt mutations in human T-lymphocytes reflect radioprotective effects of the aminothiol WR-1065, <i>Carcinogenesis</i> 17(12):2647-2653 1996
	Cronkite et al, Effects of whole body irradiation, <i>Annu. Rev. Med.</i> 3:193-214 1952
	Cronkite et al, The hemorrhagic phase of the acute radiation syndrome due to exposure of the whole body to penetrating ionizing radiation, <i>Am. J. Roentgenol. Radium Ther. Nucl. Med.</i> 67(5): 796-804 1952
	Cui et al, Apoptosis of circulating lymphocytes induced by whole body gamma-irradiation and its mechanism, <i>J Environ Pathol Toxicol Oncol.</i> 18(3): 185-189 1999
	Dalrymple et al, The Effect of 2-Mev Whole-Body X-Irradiation on Primates, <i>Radiation Res.</i> 25: 377-400 1965
	Dalrymple et al, Some effects of 400-Mev protons on primates, <i>Radiation Res.</i> 28(2):507-528 1966
	Dehnnin, Secretion by the human testis of epitestosterone, with its sulfoconjugate and precursor androgen 5-androstene-3 β ,17 α -diol, <i>J. Steroid Biochemistry Molec. Biol.</i> 44(2):171-177 1993
	De Greve et al, Fatal pulmonary toxicity by the association of radiotherapy and medroxyprogesterone acetate, <i>Cancer</i> 56(10): 2434-2436 1985
	Dietsch et al, Induction of granulocytic differentiation in myeloblasts by 17-beta-estradiol involves the leukotriene D4 receptor, <i>Recept. Signal Transduct.</i> 6(2):63-75 1996
	Dowding et al, Androst-5-ene-3 β ,17 β -diol prevents Grade 3 neutropenia in carboplatin-induced myelosuppressed macaques, 45th Annual Meeting of the American Society of Hematology (ASH): Cytokines in Cancer Treatment, Amer. Soc. Hematol. <i>Blood</i> 102(11 part 2):44b, abstract# 3878 2003
	Duarte et al, Androstane therapy of aplastic anaemia, <i>Acta Haemat.</i> 47:140-145 1972
	Dupis et al, Effects of lipid mediators on the synthesis of leukaemia inhibitory factor and interleukin 6 by human bone marrow stromal cells, <i>Cytokine</i> 10(10):781-785 1998
	Estrov et al, Enhancement of hemopoietic stem cell proliferation by prostaglandin inhibitory drugs, <i>Exp. Hematol.</i> 11(9):802-809 1983

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.2D2	APPLICATION NO. 10/602,330
	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE June 23, 2003	GROUP 1617

EXAMINER Approval Date	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PAGES, ETC.)
	Evans, et al, The erythropoietic response to anabolic therapy in patients receiving radiotherapy, <i>J. Clin. Pharmacol. New Drugs</i> 12(2):101-104 1972
	Faredin, I., et al, In vitor inhibitory effects of 16-methyl-substituted steroids on 5 α -reductase in rat and human prostates, <i>Steroids</i> , 59:568-571 1994
	Farese et al, Therapeutic efficacy of recombinant human leukemia inhibitory factor in a primate model of radiation-induced marrow aplasia, <i>Blood</i> 84(11): 3675-3678. 1994
	Farese et al, Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia, <i>J. Clin. Invest.</i> 97(9): 2145-2151 1996
	Fedorocko et al, Combined modality radioprotection: enhancement of survival and hematopoietic recovery in gamma-irradiated mice by the joint use of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and indomethacin, <i>Int. J. Immunopharmacol.</i> 18(5):329-337 1996
	Gallagher et al, Effect of testosterone enanthate (NSC-1759) on erythropoiesis in irradiated mice given marrow transfusions, <i>Cancer Chemother. Rep.</i> 52(6): 627-630 1968
	Gibson et al, Effect of X irradiation on release of prostaglandin E from marrow stromal cells in culture, <i>Radiation Res.</i> 89(3): 537-545 1982
	Goans et al, Early dose assessment following severe radiation accidents, <i>Health Physics</i> 72(4):513-518 1997
	Hallahan, D. E., et al, Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation, <i>Proc. Natl. Acad. Sci. USA</i> , 86, pp. 10104-10107, 1989
	Hernandez-Pando et al, The effects of androstenediol and dehydroepiandrosterone on the course and cytokine profile of tuberculosis in BALB/c mice, <i>Immunology</i> 95(2):234-241 1998
	Henderson et al, Dehydroepiandrosterone and 16 α -bromoepiandrosterone: inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes, <i>Carcinogenesis</i> , 2:683-686 1981
	Horn, A comparison of two androgenic hormones as leukopoietic agents in irradiated rats, <i>Oncology</i> 26(1):16-24 1972
	Huggins et al, Chemical structure of steroids in relation to promotion of growth of the vagina and uterus of the hypophysectomized rat, <i>J. Exp. Med.</i> 100:225-240 1954
	Huggins et al, Significance of the hydroxyl groups of steroids in promoting growth, <i>J. Exp. Med.</i> 100:241-246 1954
	Hyunh et al, Contrasting effects of α - and β -androstenediol on oncogenic myeloid cell lines in vitro, <i>J. Leukocyte Biology</i> 62:258-267 1997
	Insera et al, Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice, <i>Proc. Soc. Exp. Biol. Med.</i> 218:76-82 1998
	Kang et al, Dehydroepiandrosterone and β -endorphin enhance IL-12 gene expression, <i>Chemical Abstracts</i> 126(9):99 1997
	Kelemen et al, Reduction in the frequency of transplant-related complications in patients with chronic myeloid leukemia undergoing BMT preconditioned with a new, non-myeloablative drug combination, <i>Bone Marrow Transplant.</i> 21(8):747-749 1998
	Khomenko et al, A comparative analysis of the effect of anabolic compounds on the character and course of combined trauma, <i>Vestsi Natsyyanal'nai Akademii Navuk Belarusi, Seryya Biyalagichnykh Navuk</i> , 4:62-65 2001 (translation from Russian)

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.2D2	APPLICATION NO. 10/602,330
	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE June 23, 2003	GROUP 1617

EXAMINER Approval Date	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PAGES, ETC.)
	Knobil et al, Failure of methylandrostenediol to prevent compensatory atrophy of the adrenal in the rhesus monkey, <i>Endocrinology</i> 53(2):242-244 1953
	Kozubik et al, Effects of drugs inhibiting prostaglandin or leukotriene biosynthesis on postirradiation haematopoiesis in mouse, <i>Int. J. Radiat. Biol.</i> 65(3): 369-777 1994
	Laver et al, Effects of IL-1 on hematopoietic progenitors after myelosuppressive chemoradiotherapy, <i>Biotherapy</i> 1(4):293-300 1989
	Lee, S. J., et al, A novel ionizing radiation-induced signaling pathway that activates the transcription factor NF-kB, <i>Oncogene</i> , 17:1821-1826 1998
	Leroy et al, Estrogen-like effect of 5-androstene-3 β ,17 β -diol on the induction of fetal thymidine kinase in the rat uterus, <i>J. Steroid Biochem.</i> 31(4A):453-458 1988
	Mathani, M.S., et al, Synthesis of new C-19-functionalized cholesterol, <i>Steroids</i> , 59, pps 244-247, 1994
	McBride, et al, Radiotherapy for genes that cause cancer, <i>Nat. Med.</i> , 1:1215-1217, 1995
	McBride, et al, A sense of danger from radiation (Failla Memorial Lecture), <i>Radiation Research</i> , 162:1-19, 2004
	Miyamoto et al, Δ 5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells, <i>Proc. Natl. Acad. Sci. U.S. A.</i> 95(19):11083-11088 1998
	Morfin et al, Pregnenolone and dehydroepiandrosterone as precursors of native 7-hydroxylated metabolites which increase the immune response in mice. <i>J. Steroid Biochem. Mol. Biol.</i> 50(1-2):91-100 1994
	MacVittie et al, Combination therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor, <i>Blood</i> 87(10): 4129-4135 1996
	Neelis et al, The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys, <i>Blood</i> 90(7):2565-73 1997
	Partridge et al, Metabolic and clinical effects of methylandrostenediol in human subjects, <i>J. Clin. Endocrinol. Metab.</i> 13(2):189-202 1953
	Pashko, L. et al, "Inhibition of DNA synthesis in mouse epidermis and breast epithelium by dehydroepiandrosterone and related steroids", <i>Carcinogenesis</i> , 2(8):717-721 1981
	Pfeifer et al, Steroid profiles of healthy individuals, <i>J. Chromatogr.</i> 223(1):21-32 1981
	Raju, U., et al, IkB α degradation is not a requirement for the X-ray-induced activation of nuclear factor κ B in normal rat astrocytes and human brain tumour cells, <i>Int. J. Radiat. Biol.</i> , 74:617-624, 1998
	Rodgers et al, Acquired cyclic neutropenia: successful treatment with prednisone, <i>Am. J. Hematol.</i> 13(1):83-89 1982
	Rosenfeld et al, Metabolism and interconversion of dehydroisoandrosterone and dehydroisoandrosterone sulfate, <i>J. Clin. Endocrinol. Metab.</i> 35(2):187-193 1972
	Rubin, P., et al, A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis, <i>Int. J. Radiat. Oncol. Biol. Phys.</i> , 33, pp. 99-109, 1995
	Segaloff et al, Hormonal therapy in cancer of the breast . II. Effects of methylandrostenediol on clinical course and hormonal excretion, <i>Cancer</i> 5(2):271-274 1952
	Segaloff et al, Hormonal therapy in cancer of the breast. IV. Effect of androstenediol on clinical course and hormonal excretion, <i>Cancer</i> 5(6):1179-1181 1952

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.2D2	APPLICATION NO. 10/602,330
	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE June 23, 2003	GROUP 1617

EXAMINER Approval Date	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PAGES, ETC.)
	Segaloff et al, Hormonal therapy in cancer of the breast. V. The effect of methyltestosterone on clinical course and hormonal excretion, <i>Cancer</i> 6(3):483-487 1953
	Segaloff, Testosterone and miscellaneous steroids in the treatment of advanced mammary cancer, <i>Cancer</i> 10(4):808-812 1957
	Segaloff et al, Hormonal therapy in cancer of the breast. XI. The effect of dehydroepiandrosterone on clinical course and hormonal excretion, <i>Cancer</i> 10(6):1114-1115 1957
	Segaloff et al, Hormonal therapy in cancer of the breast. XIII. The effect of 9 α -fluoro-17 α -methyl- Δ^4 -androsten-3-one-11 β , 17 β -diol (Fluoxymesterone) therapy on clinical course and hormonal excretion. <i>Cancer</i> 11(6):1187-1189 1958
	Singer et al, Steroids and hematopoiesis. II. The effect of steroids on in vitro erythroid colony growth: evidence for different target cells for different classes of steroids, <i>J. Cell Physiol.</i> 88(2):135-143 1976
	Singer et al, Steroids and hematopoiesis. III. The response of granulocytic and erythroid colony-forming cells to steroids of different classes, <i>Blood</i> 48(6):855-864 1976
	Stenke, L., et al., Leukotrienes and lipoxins – new potential performers in the regulation of human myelopoiesis, <i>Leukemia Research</i> , 18 (10), pp 727-732, 1994
	Steinetz et al, Pyrogenicity of etiocholanolone and interleukin-1 in New and Old World Monkeys, <i>Proc. Soc. Exp. Biol. Med.</i> 217(4):435-438 1998
	Stewart et al, Lymphohematopoietic engraftment in minimally myeloablated hosts, <i>Blood</i> 91(10):3681-3687 1998
	Stickney et al, HE2100 protects irradiated rhesus macaques against "Hematopoietic Syndrome", 45th Annual Meeting of the American Society of Hematology (ASH): Cytokines in Cancer Treatment, Amer. Soc. Hematol., <i>Blood</i> 102(11 part 1):9a-10a, abstract# 20 2003
	Stork et al, Interleukin-1 accelerates murine granulocyte recovery following treatment with cyclophosphamide, <i>Blood</i> 73(4):938-944 1989
	Syljuasen, R. G., et al, Apoptosis and delayed expression of c-jun and c-fos after gamma irradiation of Jurkat T cells, <i>Radiat. Res.</i> , 146:276-282 1996
	Tabbara, I. A., et al, The role of granulocyte colony-stimulating factor in hematopoietic stem cell transplantation, <i>Cancer Invest</i> , 15 (4), pp. 353-356, 1997
	Tabbara, I. A., et al, The clinical applications of granulocyte colony-stimulating factor in hematopoietic stem cell transplantation: a review, <i>Anticancer Res</i> , 19 (6B) pp. 3901-3905, 1996
	Udupa et al, Acceleration of granulopoietic recovery by androgenic steroids in mice made neutropenic by cytotoxic drugs, <i>Cancer Res.</i> 34(10):2517-2520 1974
	Uralets et al, Over-the-counter anabolic steroids 4-androsten-3,17-dione; 4-androsten- 3beta,17beta-diol; and 19-nor-4-androsten-3,17-dione: excretion studies in men, <i>J. Anal. Toxicol.</i> 23(5):357-366 1999
	Wagemaker et al, The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation, <i>Stem Cells</i> 16(6):375-386 1998
	Walker and Cervený eds., Textbook of military medicine, vol. 2, Medical consequences of nuclear warfare; Acute radiation syndrome in humans, Office of the Surgeon General, Falls Church, Va., U.S.A. pg. 15-36 1989
	Ward, DNA damage produced by ionizing radiation in mammalian cells: Identities, mechanisms of formation and repairability, <i>Prog. Nucleic Acids Res. Mol. Biol.</i> , 35:96-128 1988
	Welte et al, Recombinant human granulocyte colony-stimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates, <i>J. Exp. Med.</i> 165(4):941-948 1987

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. 202.2D2	APPLICATION NO. 10/602,330
	APPLICANT Clarence N. Ahlem, et al	
	FILING DATE June 23, 2003	GROUP 1617

EXAMINER Approval Date	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PAGES, ETC.)
	Whitnall et al, Molecular specificity of 5-androstenediol as a systemic radioprotectant in mice, <i>Immunopharmacol. Immunotoxicol.</i> 27:15-32 2005
	Whitnall et al, Androstenediol stimulates myelopoiesis but not lymphopoiesis in irradiated mice, <i>Blood</i> 90(10 Suppl. 1 Part 1):175a 1997
	Wiegers, G. J., et al, Enhancement of rat splenic lymphocyte mitogenesis after short term preexposure to corticosteroids in vitro, <i>Endocrinology</i> , 135(8):2351-2357, 1994
	Xia et al, Anti-AIDS agents. Part 36: 17-Carboxylated steroids as potential anti-HIV agents, <i>Bioorganic & Medicinal Chem.</i> 7:1907-1911 1999
	Yang et al, Inhibition of HIV-1 Latency Reactivation by Dehydroepiandrosterone (DHEA) and an Analog of DHEA, <i>Aids Research and Human Retroviruses</i> 9(8):747-754 1993
	Younglai et al, The in vivo metabolism of 16-alpha-hydroxydehydroisoandrosterone in man, <i>Biochemistry</i> 6(7):2040-2052 1967
	Zhang et al, Prevention if immune dysfunction and vitamin E loss by dehydroepiandrosterone and melatonin supplementation during murine retrovirus infection, <i>Immunology</i> 96:291-297 1999
	Zhang et al, Ionizing radiation-induced IL-1 alpha, IL-6 and GM-CSF production by human lung cancer cells, <i>Chinese Med. J. (Engl)</i> 107(9):653-657 1994
	Zhu, B., et al, Strong inhibition of estrone-3-sulfatase activity by pregnenolone 16 α -carbonitrile but not by several analogs lacking a 16 α -nitrile group, <i>Steroids</i> , 65:521-527, 2000

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	